
Sign up to save your podcasts
Or


Biogen falls 30% after halting trials for its Alzheimer’s drug. Healthcare analyst (and Industry Focus host) Shannon Jones discusses potential next moves for the suddenly-embattled pharmaceutical company. CVS starts selling cannabis products in eight states. Plus, a federal judge sides with the maker of Dum Dum lollipops in a battle against Tootsie Roll.
Get $50 off your first job post at www.LinkedIn.com/Fool.
By The Motley Fool4.7
16041,604 ratings
Biogen falls 30% after halting trials for its Alzheimer’s drug. Healthcare analyst (and Industry Focus host) Shannon Jones discusses potential next moves for the suddenly-embattled pharmaceutical company. CVS starts selling cannabis products in eight states. Plus, a federal judge sides with the maker of Dum Dum lollipops in a battle against Tootsie Roll.
Get $50 off your first job post at www.LinkedIn.com/Fool.

3,221 Listeners

1,502 Listeners

806 Listeners

948 Listeners

516 Listeners

1,182 Listeners

2,172 Listeners

826 Listeners

1,418 Listeners

1,038 Listeners

9,627 Listeners

194 Listeners

809 Listeners

76 Listeners

38 Listeners

1,001 Listeners

44 Listeners